Salinomycin

• UNSPSC Description:

  Salinomycin (Procoxacin), a polyether potassium ionophore antibiotic, selectively inhibits the growth of gram-positive bacteria. Salinomycin is a potent inhibitor of Wnt/β-catenin signaling, blocks Wnt-induced LRP6 phosphorylation. Salinomycin (Procoxacin) shows selective activity against human cancer stem cells[1][2][3].

• Target Antigen:

  Antibiotic; Apoptosis; Autophagy; Bacterial; Mitophagy; Parasite; Wnt; β-catenin

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Apoptosis;Autophagy;Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Salinomycin.html

• Solubility:

  DMSO : ≥ 36.7 mg/mL

• Smiles:

  [H][C@]1([C@](C)(CC2)O[C@]32[C@H](O)C=C[C@]4(O[C@]([H])([C@@H](CC)C([C@@H](C)[C@@H](O)[C@H](C)[C@]5([H])O[C@]([C@@H](CC)C(O)=O)([H])CC[C@@H]5C)=O)[C@@H](C)C[C@H]4C)O3)CC[C@@](CC)(O)[C@H](C)O1

• Molecular Weight:

  751.00

• References & Citations:

  [1]Lu D, et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13253-7.|[2]Zhou J, et al. Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactiveoxygen species. Toxicol Lett. 2013 Oct 24;222(2):139-45.|[3]Wang F, et al. Salinomycin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells In Vitro and In Vivo. PLoS One. 2012; 7(12): e50638.|[4]Qu H, et al. Effect of salinomycin on metastasis and invasion of bladder cancer cell line T24. Asian Pac J Trop Med. 2015 Jul;8(7):578-82.|[5]Klose J, et al. Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model. PLoS One. 2019 Feb 14;14(2):e0211916.|[6]Naujokat C, et al. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012;2012:950658.ACS Infect Dis. 2021 Aug 13;7(8):2390-2401.|Acta Biomater. 2022 Aug 23;S1742-7061(22)00501-3.|Anal Chem. 2022 Sep 19.|Biomed J. 2020 Aug;43(4):368-374.|bioRxiv. 2020 Jun.|bioRxiv. 2023 Jan 17.|bioRxiv. 2023 Jun 25.|bioRxiv. 2024 September 07.|bioRxiv. 2024 September 18.|Biosens Bioelectron. 2024 Jul 1:255:116245.|Cancers. 2020 Aug 5;12(8):2176.|Cell Biosci. 2021 Aug 4;11(1):156.|Cell Commun Signal. 2018 Nov 23;16(1):89.|Cell Death Dis. 2023 Mar 11;14(3):193.|Cell Oncol (Dordr). 2024 Oct 7.|Chemosphere. 2024 Jul 3:142758.|EMBO Mol Med. 2019 Oct;11(10):e9930.|Eur J Med Chem. 2024 Oct 5:276:116701.|Int J Mol Med. 2019 Oct;44(4):1289-1298.|Int J Mol Sci. 2019 Jun 12;20(12):2861.|Int J Mol Sci. 2023 Mar 21;24(6):5939.|Int J Nanomedicine. 2020 Sep 15;15:6839-6854.|J Bioenerg Biomembr. 2021 Aug 8.|J Control Release. 2020 Oct 10;326:387-395.|Norwegian University of Science and Technology. Department of Clinical and Molecular Medicine. 2021 Oct.|Oncol Rep. 2018 Aug;40(2):877-886.|Pharmacol Res. 2020 May;155:104751.|RSC Adv. 2021 Nov 2;11(56):35331-35341.|Viruses. 2022, 14(8), 1734.|AAPS PharmSciTech. 2024 Sep 7;25(7):211.|Eur J Med Chem. 2024 Oct 5:276:116701.|Exp Ther Med. 2020 Mar;19(3):1835-1843.|Int J Pharm. 2023 Feb 24;122779.|SSRN. 2024 Nov 12.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  53003-10-4